An immunogenic composition comprising a continuous aqueous phase and at least two dispersed phases 1 and 2 as droplets wherein: - the dispersed phase 1 comprises: - an amphiphilic lipid 1, - a solubilizing lipid 1 comprising at least one fatty acid glyceride, - a co-surfactant 1 comprising at least one chain consisting of alkylene oxide units, - a surfactant 1 bearing an antigen of the following formula (I): (L 1 -X 1 -H 1 -Y 1 ) v -G-Z 1 -Ag (I), wherein: - L 1 represents a lipophilic group, - X 1 , Y 1 , Z 1 and G represent independently a binding group, - H 1 represents a hydrophilic group comprising a polyalkoxylated chain, - v is an integer from 1 to 8, and - Ag represents an antigen, wherein the molar ratio of the surfactant 1 bearing an antigen of formula (I) over the sum of the co-surfactant 1 and of the surfactant 1 bearing an antigen of formula (I) is from 0.01% to 5%, and - the dispersed phase 2 comprises: - an amphiphilic lipid 2, - a solubilizing lipid 2 comprising at least one fatty acid glyceride, - a co-surfactant 2 comprising at least one chain consisting of alkylene oxide units, - an immunostimulating agent 2 bearing at least an anionic group, and - a cationic surfactant 2, with the proviso that the dispersed phase 2 is free of surfactant bearing an antigen of formula (I). - the dispersed phase 1 comprises: - an amphiphilic lipid 1, - a solubilizing lipid 1 comprising at least one fatty acid glyceride, - a co-surfactant 1 comprising at least one chain consisting of alkylene oxide units, - a surfactant 1 bearing an antigen of the following formula (I): (L 1 -X 1 -H 1 -Y 1 ) v -G-Z 1 -Ag (I), wherein: - L 1 represents a lipophilic group, - X 1 , Y 1 , Z 1 and G represent independently a binding group, - H 1 represents a hydrophilic group comprising a polyalkoxylated chain, - v is an integer from 1 to 8, and - Ag represents an antigen, wherein the molar ratio of the surfactant 1 bearing an antigen of formula (I) over the sum of the co-surfactant 1 and of the surfactant 1 bearing an antigen of formula (I) is from 0.01% to 5%, and - an amphiphilic lipid 1, - a solubilizing lipid 1 comprising at least one fatty acid glyceride, - a co-surfactant 1 comprising at least one chain consisting of alkylene oxide units, - a surfactant 1 bearing an antigen of the following formula (I): (L 1 -X 1 -H 1 -Y 1 ) v -G-Z 1 -Ag (I), wherein: - L 1 represents a lipophilic group, - X 1 , Y 1 , Z 1 and G represent independently a binding group, - H 1 represents a hydrophilic group comprising a polyalkoxylated chain, - v is an integer from 1 to 8, and - Ag represents an antigen, wherein the molar ratio of the surfactant 1 bearing an antigen of formula (I) over the sum of the co-surfactant 1 and of the surfactant 1 bearing an antigen of formula (I) is from 0.01% to 5%, and - L 1 represents a lipophilic group, - X 1 , Y 1 , Z 1 and G represent independently a binding group, - H 1 represents a hydrophilic group comprising a polyalkoxylated chain, - v is an integer from 1 to 8, and - Ag represents an antigen, - the dispersed phase 2 comprises: - an amphiphilic lipid 2, - a solubilizing lipid 2 comprising at least one fatty acid glyceride, - a co-surfactant 2 comprising at least one chain consisting of alkylene oxide units, - an immunostimulating agent 2 bearing at least an anionic group, and - a cationic surfactant 2, with the proviso that the dispersed phase 2 is free of surfactant bearing an antigen of formula (I). - an amphiphilic lipid 2, - a solubilizing lipid 2 comprising at least one fatty acid glyceride, - a co-surfactant 2 comprising at least one chain consisting of alkylene oxide units, - an immunostimulating agent 2 bearing at least an anionic group, and - a cationic surfactant 2, <EOS>